Delta-Fly Pharma, Inc. (TYO:4598)
Japan · Delayed Price · Currency is JPY 109.00
-1.00 (-0.91%)
Aug 6, 2026, 3:09 PM JST
Delta-Fly Pharma Market Cap
Delta-Fly Pharma has a market cap or net worth of 1.57 billion as of August 5, 2026. Its market cap has decreased by -76.76% in one year.
Market Cap
1.57B
Enterprise Value
1.43B
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
109.00
ChartMarket Cap Chart
Since October 12, 2018, Delta-Fly Pharma's market cap has decreased from 21.91B to 1.57B, a decrease of -92.82%. That is a compound annual growth rate of -28.59%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 6, 2026 | 1.57B | -74.63% |
| Dec 30, 2025 | 6.20B | 18.44% |
| Dec 30, 2024 | 5.24B | -37.32% |
| Dec 29, 2023 | 8.35B | 21.17% |
| Dec 30, 2022 | 6.89B | -14.46% |
| Dec 30, 2021 | 8.06B | 49.71% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Oct 12, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Cyfuse Biomedical K.K. | 5.20B |
| D. Western Therapeutics Institute | 4.60B |
| Kohjin Bio | 4.52B |
| TMS Co., Ltd. | 4.51B |
| Ribomic | 4.24B |
| Transgenic Group | 3.56B |
| Human Metabolome Technologies | 3.29B |
| Modalis Therapeutics | 3.11B |